← FDA DRUG APPROVALS

FDA ANDA · ANDA072370

DIAZEPAM

Sponsor: WATSON LABS INC

APPLICATION
ANDA072370
TYPE
ANDA
ORIGINAL APPROVAL
1993-01-29
LATEST ACTION
2023-08-10
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

DIAZEPAMDiscontinued
DIAZEPAM 5MG/ML · INJECTABLE · INJECTION

Approval history

2023-08-10Labeling · Supplement 11 · standardAP
2023-01-17Labeling · Supplement 10 · standardAP
2021-08-26Labeling · Supplement 8 · standardAP
2021-08-26Labeling · Supplement 9 · standardLabelAP
2021-02-08Labeling · Supplement 7 · standardAP
2016-12-16Labeling · Supplement 6 · standardAP
1996-08-15Manufacturing (CMC) · Supplement 4AP
1996-08-15Manufacturing (CMC) · Supplement 2AP
1996-08-15Manufacturing (CMC) · Supplement 5AP
1996-08-15Labeling · Supplement 3AP
1994-03-23Manufacturing (CMC) · Supplement 1AP
1993-01-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →